Update on progress in Unilever partnership

Aptamer Group, the developer of novel Optimer® binders to enable innovation in the life sciences industry, is providing an update on the partnership with Unilever to deliver Optimer binders for cosmetic applications.

In 2022, Aptamer initiated a partnership with Unilever for the development of Optimer binders with the aim of treating malodour in personal care products. Following successful Optimer development, the binders have been rigorously tested at both Aptamer Group and Unilever showing highly positive and reproducible results, indicating their potential for use in downstream products.

Based on these results, a patent was submitted on 28 March 2024, to protect the developed Optimer binders and give Aptamer Group precedence for the protection of the intellectual property.

Work to test the Optimer binders is ongoing in Unilever’s labs. Unilever plans to conduct on-person functionality studies in the second half of 2024.

The global deodorant market alone was valued at $25.6 billion in 2023, with Unilever being the market leader as the largest antiperspirant and deodorant manufacturer in the world.

It is anticipated that this project will be completed over the next two years, and if successful, could result in Aptamer licensing the Optimer binders to Unilever.

“I’m pleased to provide this update on our work with Unilever. The early success we have seen to date in evaluating our Optimers that aim to treat malodour has been promising. We are excited to support our partners at Unilever in advancing these binders to the next stage of development with on-person functionality studies. Fast-moving consumer goods (FMCG) like personal care products can progress to market more rapidly than diagnostics or therapeutic products. Optimers offer advantages such as stability, shelf life and consistent manufacturability making them ideal molecules for FMCG / cosmetic applications.  If the Optimer binders continue to progress through the testing and manufacturing stages in Unilever’s hands, then we anticipate the completion of this project within two years.”

Dr Arron Tolley, Chief Technical Officer of Aptamer Group


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Aptamer Group. (2024, July 09). Update on progress in Unilever partnership. News-Medical. Retrieved on July 24, 2024 from https://www.news-medical.net/news/20240709/Update-on-progress-in-Unilever-partnership.aspx.

  • MLA

    Aptamer Group. "Update on progress in Unilever partnership". News-Medical. 24 July 2024. <https://www.news-medical.net/news/20240709/Update-on-progress-in-Unilever-partnership.aspx>.

  • Chicago

    Aptamer Group. "Update on progress in Unilever partnership". News-Medical. https://www.news-medical.net/news/20240709/Update-on-progress-in-Unilever-partnership.aspx. (accessed July 24, 2024).

  • Harvard

    Aptamer Group. 2024. Update on progress in Unilever partnership. News-Medical, viewed 24 July 2024, https://www.news-medical.net/news/20240709/Update-on-progress-in-Unilever-partnership.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Aptamer Group collaborates with world-leading pharmaceutical company to evaluate Optimer technology